rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1
|
pubmed:dateCreated |
1977-10-28
|
pubmed:abstractText |
1. 19-Nor-17alpha-pregna-1,3,5(10)-trien-20-yne-3,17-diol (ethynyloestradiol) or 17beta-hydroxy-19-nor-17alpha-pregn-4-en-20-yn-3-one (norethindrone) but not 17alpha-ethyl-17beta-hydroxy-19-norandrost-4-en-3-one (norethandrolone) caused a time-dependent loss of cytochrome P-450 when incubated in vitro with rat liver microsomal fractions and NADPH-generating systems. 2. The enzyme system catalysing the norethindrone-mediated loss of cytochrome P-450 had many characteristics of the microsomal mixed-function oxidases. It required NADPH and air, and was inhibited by Co. However, it was unaffected by 1 mM-compound SKF 525A. 3. In microsomal fractions from phenobarbitone-pretreated rats the norethindrone-mediated loss of cytochrome P-450 was increased relative to controls. The norethindrone-mediated cytochrome P-450 loss was less pronounced when the animals were pretreated with 3beta-hydroxy-pregn-5-en-2-one 16alpha-carbonitrile (pregnenolone 16alpha-carbonitrile). Pretreatment with 3-methylcholanthrene rendered the animals resistant to the norethindrone effect. 4. Administration in vivo [100mg/kg, intraperitoneally] of norethindrone or ethinyl oestradiol also produced a time-dependent loss of liver cytochrome P-450. Norethandrolone had a similar, though much less-marked, effect. All three steroids lead to an induction of 5-aminolaevulinate synthase and an accumulation of porphyrins in the liver. 5. The loss of cytochrome P-450 and the accumulation of porphyrins in the liver 2 h after the administration of norethindrone to female rats was similar to that seen in males. 6. Rats pretreated with phenobarbitone and given norethindrone or ethynyloestradiol (100mg/kg, intraperitoneally) formed green pigments in their livers. These had characteristics similar to the green pigments produced in the livers of rats after the administration of 2-allyl-2-isopropylacetamide. No green pigments could be extracted from the livers of control rats or those given norethandrolone, oestradiol or progesterone.
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-1001715,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-1181022,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-13264058,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-13295297,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-14209971,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-14209972,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-14268846,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-14907713,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-164874,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-241614,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-4132898,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-4146295,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-4149394,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-4150135,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-4210249,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-4342728,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-4367955,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-4370072,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-4383307,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-4390401,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-4647071,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-4823112,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-5008942,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-5131732,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-5134533,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-5171464,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-5787863,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-5935350,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-5971440,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-61382,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-793893,
http://linkedlifedata.com/resource/pubmed/commentcorrection/901418-942437
|
pubmed:keyword |
http://linkedlifedata.com/resource/pubmed/keyword/ANABOLIC STEROIDS,
http://linkedlifedata.com/resource/pubmed/keyword/Animals, Laboratory,
http://linkedlifedata.com/resource/pubmed/keyword/Biology,
http://linkedlifedata.com/resource/pubmed/keyword/Clinical Research,
http://linkedlifedata.com/resource/pubmed/keyword/Contraception,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents...,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents...,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents...,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents, Female--side...,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents...,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents...,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive...,
http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents--side effects,
http://linkedlifedata.com/resource/pubmed/keyword/ENZYMES,
http://linkedlifedata.com/resource/pubmed/keyword/Enzymes And Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/keyword/Ethinyl Estradiol--administraction...,
http://linkedlifedata.com/resource/pubmed/keyword/Ethinyl Estradiol--side effects,
http://linkedlifedata.com/resource/pubmed/keyword/Family Planning,
http://linkedlifedata.com/resource/pubmed/keyword/Hepatic Effects,
http://linkedlifedata.com/resource/pubmed/keyword/Norethindrone--administraction and...,
http://linkedlifedata.com/resource/pubmed/keyword/Norethindrone--side effects,
http://linkedlifedata.com/resource/pubmed/keyword/Physiology,
http://linkedlifedata.com/resource/pubmed/keyword/Research Methodology
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0264-6021
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
166
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
57-64
|
pubmed:dateRevised |
2009-11-18
|
pubmed:otherAbstract |
PIP: The effects of norethindrone (NEI), norethandrolone (NEA), and ethinyl estradiol (EE) on liver cytochrome P-450 in rats were studied. Rats were pretreated with phenobarbitone sodium (80 mg/kg for 3 days), 3-methyl cholanthrene (20 mg/kg for 3 days), and pregnenolone 16alpha-carbonitrite (75 mg/kg twice daily for 3 days). NEI, NEA, and EE were given at a dose of 100 mg/kg. Liver microsomal fractions were prepared and determinations of cytochromes P-450 and b5 made. Steroids were also incubated with liver mitochondrial preparations and P-450 measured. Liver porphyrins were determined as were mitochondrial 5-aminolaevulinate synthase activity. Isolation of green pigments was undertaken. NEI and EE caused a time-dependent loss of cytochrome P-450 when incubated in vitro with rat microsomal fractions and NADPH-generating systems. The effect of pretreatment of rats with inducers of mixed-function oxidases on the steroid mediated loss of cytochrome P-450 in vitro were: 1) phenobarbitone stimulated P-450 breakdown, 2) methylcholanthrene-induced cytochrome P-448 was unaffected, and 3) pregnenolone was without effect. The enzyme system involved in the NEI breakdown of P-450 has many of the characteristics of the microsomal mixed-function oxidases. In vivo, there was a marked decrease in P-450 (52%) after a single injection of NEI. Cytochrome b5 was minimally affected. Loss of P-450 was accompanied by increasing porphyrin levels. NEI, NEA, and EE caused a 3.2-fold induction of 5-aminolaevulinate synthase activity. Rats pretreated with phenobarbitone and given NEI or EE formed green pigments. While metabolic pathways differ between the species, it is suggested that long-term estrogen therapy might predispose some individuals to the type of porphyria associated with the side effects of these compounds.
|
pubmed:meshHeading |
pubmed-meshheading:901418-5-Aminolevulinate Synthetase,
pubmed-meshheading:901418-Animals,
pubmed-meshheading:901418-Cytochrome P-450 Enzyme System,
pubmed-meshheading:901418-Enzyme Induction,
pubmed-meshheading:901418-Ethinyl Estradiol,
pubmed-meshheading:901418-Female,
pubmed-meshheading:901418-Liver,
pubmed-meshheading:901418-Male,
pubmed-meshheading:901418-Microsomes, Liver,
pubmed-meshheading:901418-Norethindrone,
pubmed-meshheading:901418-Porphyrins,
pubmed-meshheading:901418-Rats,
pubmed-meshheading:901418-Time Factors
|
pubmed:year |
1977
|